Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly sues partner Valeant over Permax US liability costs

This article was originally published in Scrip

Executive Summary

Lillyis suing its partner, Valeant Pharmaceuticals International, for breach of contract, alleging that Valeant failed to share the cost of product liability claims arising from the withdrawal of the Parkinson's disease treatment pergolide (Permax). The lawsuit was filed on December 24th in the US District Court for the Southern District of Indiana. Permax was originally developed by Lilly, but the US rights were later granted to Valeant; in the suit Lilly claims that the agreement covered sharing costs of product liability claims "alleged to have been caused by use of Permax sold in the US". In 2007, the product was voluntarily pulled from the market because of the FDA’s concern over the history of a high rate of cardiac valvular disease (heart valve regurgitation; Scrip Online, March 30th, 2007). Valeant claimed the cost-sharing obligations would take effect "only if the product liability claim at issue was caused by Valeant’s misconduct", according to the suit, an interpretation that Lilly disputes. Lilly states in the suit that "Valeant breached the Lilly/Valeant agreement by failing to share costs, as required by the Lilly/Valeant agreement, associated with a product liability claim".

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008115

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel